Skip to main content
. 2020 Jul 16;15(2):546–555. doi: 10.1016/j.stemcr.2020.06.014

Table 1.

Clinical Trials on the Basis of hPSCs by the End of 2019

ICD-10 Main Chapter Disease ICD-10 Cellular Origin of Cell Product
hESC hiPSC hpPSC SCNT-hESC Total
Neoplasms malignant neoplasms (advanced solid tumors) 0 2 0 0 5
malignant neoplasm of bronchus and lung 1 0 0 0
myeloid leukemia 0 1 0 0
Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism beta-thalassemia 0 2 0 0 2
Endocrine, nutritional, and metabolic diseases type 1 diabetes mellitus 4 1 0 0 6
primary ovarian failure 1 0 0 0
Diseases of the nervous system Parkinson's disease 0 3 2 0 6
motor neuron disease 1 0 0 0
Diseases of the eye and adnexa other retinal disorders 4 0 0 0 25
degeneration of macula and posterior pole: senile macular degeneration, dry age-related macular degeneration 10 1 0 1
hereditary retinal dystrophy: Retinitis pigmentosa 2 0 0 0
hereditary retinal dystrophy: Stargardt disease 5 0 0 0
other specified disorders of cornea (limbal stem cell deficiency) 0 1 0 0
degeneration of macula and posterior pole: wet age-related macular degeneration 0 1 0 0
Diseases of the circulatory system ischemic heart diseases 1 4 0 0 7
cerebral infarction, unspecified 0 2 0 0
Diseases of the musculoskeletal system and connective tissue derangement of meniscus due to old tear or injury 1 0 0 0 1
Injury, poisoning, and certain other consequences of external causes injury of spinal cord, level unspecified 2 0 0 0 3
bone marrow transplant rejection 0 1 0 0
32 19 2 1 54

Given are diseases targeted by the respective studies and the number of studies involving hESC-, hiPSC-, hpPSC-, and SCNT-hESC-derived cell products. Two Food and Drug Administration-approved hESC studies withdrawn before enrollment are not included.